Developer docs
API playgroundTry for free, no card

Search company profiles

ENPICOM

Full company profile

uuid0003cai

Namestring
ENPICOM
Legal namestring
ENPICOM B.V.
Websiteurl
enpicom.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

ENPICOM B.V. is a Netherlands-based bioinformatics software company founded in 2015 and headquartered in 's-Hertogenbosch. The company builds the ENPICOM Platform, a SaaS-based discovery operating system designed specifically for biologics — primarily antibody and immune-repertoire discovery workflows used by pharmaceutical and biotechnology companies. The platform processes NGS, Sanger, and single-cell sequencing data at scale, delivering end-to-end pipelines for in vitro and in vivo antibody lead selection, including clone annotation, quality control, clonotype clustering, enrichment analysis, developability analysis, and candidate prioritization.

The technology stack is biologics-specific rather than generic lab automation, with integrated modules covering pipeline automation, an AI Agent interface (exposed via the Model Context Protocol), ML model integration, and system integration with existing LIMS, ELNs, data lakes, and CRO deliverables. ENPICOM holds ISO 27001 certification and deploys engineering teams alongside client scientists to scope and build tailored pipelines, typically live within 4-8 weeks. The company also produces the 'Models & Molecules' podcast as a content and thought-leadership channel.

ENPICOM operates a direct enterprise sales motion with quote-based annual subscriptions and bundled professional services for pipeline deployment. The customer base spans top-10 pharmaceutical companies, biotech firms, academic institutions, and a network of 27+ partner organizations including Illumina, Carterra, LifeArc, NGM Bio, and Erasmus MC. Total disclosed equity funding is approximately $1.36 million across two rounds (2015 and 2019), with investors including Arches Capital, BOM Brabant Ventures, NextGen Ventures, and ACE Incubator. The leadership team is led by founder and CEO Nicola Bonzanni, with Jorrit Posthuma as CTO, Pim Fuchs as CAIO, Pablo Mendes de León as CFO & COO, and Ron van Eijsden as CBO.

Short descriptiontext

ENPICOM B.V. is a Netherlands-based bioinformatics software company (founded 2015) that provides a SaaS discovery operating system for antibody and immune-repertoire workflows, serving top-10 pharma, biotech, and academic customers with integrated pipeline automation, ML, and AI-agent capabilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDen Bosch, Netherlands
HQ citystring
Den Bosch
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioinformatics software, antibody discovery, biologics analytics, immune repertoire analysis, sequencing data platform
Industry4 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Software Publishers513210
  • Computer Systems Design and Related Services54151
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Computer Integrated Systems Design7373
Product category
Bioinformatics Software for Antibody & Biologics Discovery
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1SaaS Platform Subscription
TypeSubscription Recurring
Description

ENPICOM provides its discovery platform as a SaaS product. Customers pay subscription fees for access to the platform, with pipeline deployment and engineering support included as part of the engagement. Terms indicate automatic annual renewal unless terminated two months before expiry.

enpicom.com
2Professional Services (Pipeline Deployment)
TypeProfessional Services
Description

ENPICOM deploys a team of engineers alongside client scientists to scope, build, and deploy tailored discovery pipelines within 4-8 weeks. This engineering deployment is a core component of the commercial engagement model.

enpicom.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1No public tier structure disclosed
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based engagement; no public pricing available. Pipeline deployment and platform access are sold as a bundled engagement.

enpicom.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1ENPICOM Platform
Description

The operating system for biologics discovery - a software platform providing end-to-end environment for analysis-workflow orchestration covering immune-repertoire and antibody sequence analysis, data integration, assay and screening management, and developability tracking.

enpicom.com
+1 more record
Core offering1 text field

ENPICOM provides a SaaS-based discovery operating system that ingests sequencing data and applies AI- and ML-driven analytics for antibody and biologics discovery. The platform supports in vitro and in vivo discovery workflows, automates end-to-end pipelines, and exposes an MCP-based Agent Interface so AI agents can interact with discovery data. The offering is targeted at pharma, biotech, and academic researchers developing therapeutic antibodies and other biologics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 4× faster pipeline deployment — pipelines live in 4-8 weeks, not a 12-month implementation project
+7 more records
Product overview1 text field

ENPICOM offers a unified platform-plus-modules architecture centered on the ENPICOM Platform — a discovery operating system for biologics. The core platform provides end-to-end analysis-workflow orchestration for immune-repertoire and antibody sequence analysis, processing billions of sequences in hours. The product portfolio comprises two primary solution modules — In vitro Antibody Discovery and In vivo Antibody Discovery — which cover clone annotation, quality control, clonotype clustering, enrichment analysis, developability analysis, and candidate prioritization. Supporting capability modules include Pipeline Automation, Agent Interface, AI Adoption (ML model integration), and System Integration. ENPICOM also produces the Models & Molecules Podcast as a content/marketing sub-brand. Note: An older IGX Platform is referenced in historical terms and conditions but appears superseded by the current ENPICOM Platform.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership27 partners
Strategic tierCoreTypeTechnology or Integration
Description

Illumina is listed as a partner logo on ENPICOM's website, indicating a technology integration or collaboration. Illumina provides next-generation sequencing (NGS) platforms that are a core data source for ENPICOM's discovery pipelines. ENPICOM connects to sequencing platforms including Illumina as part of its end-to-end pipeline automation.

Strategic tierCoreTypeTechnology or Integration
Description

Carterra is listed as a partner logo. Carterra provides high-throughput antibody screening and characterization platforms. The partnership integrates Carterra's experimental data with ENPICOM's analytical pipelines.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

LifeArc is listed as a partner logo. LifeArc is a UK-based medical research charity engaged in translational biomedical research and drug discovery, indicating a co-development or strategic collaboration in antibody discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Erasmus MC (Erasmus University Medical Center Rotterdam) is listed as a partner logo, representing a strategic collaboration with a leading academic medical center for biologics and immunology research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

University of Oxford is listed as a partner logo. The collaboration connects ENPICOM's discovery platform with Oxford's academic research capabilities in antibody discovery and immunology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Weizmann Institute of Science is listed as a partner logo. The collaboration provides access to cutting-edge immunology research capabilities for biologics discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

UCL is listed as a partner logo, representing a collaboration with one of the UK's leading research universities for biologics and computational biology research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Radboud University (Nijmegen, Netherlands) is listed as a partner logo, indicating a collaboration in academic biologics and immunology research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ghent University (Universiteit Gent) is listed as a partner logo, representing a research collaboration in biologics discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

VU Amsterdam is listed as a partner logo, indicating a research collaboration with one of Amsterdam's major universities in the field of immunology and biologics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Utrecht University is listed as a partner logo, representing a collaboration with a leading Dutch research university in antibody and biologics research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Aalborg University (Denmark) is listed as a partner logo, indicating a research collaboration in computational biology and biologics discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

TUM is listed as a partner logo, representing a collaboration with a leading German technical university in computational life sciences and biologics research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

KGI is listed as a partner logo. Keck Graduate Institute in Claremont, CA specializes in applied life sciences and biotech, indicating a collaboration in biologics education and/or research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

University of Michigan is listed as a partner logo, representing a collaboration with a leading US research university in computational biology and antibody discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Queen Mary University of London is listed as a partner logo, indicating a research collaboration in biologics and immunology.

17Inno4vac
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Inno4vac is listed as a partner logo. Inno4vac is focused on innovation in vaccine and immunotherapy development, suggesting a collaborative effort in biologics discovery methodologies.

enpicom.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mabylon is listed as a partner logo, representing a collaboration with a biotech company engaged in antibody discovery and development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Memo Therapeutics is listed as a partner logo, indicating a collaborative relationship with a biotech company specializing in antibody discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Kling Biotherapeutics is listed as a partner logo, representing a collaboration with a biotherapeutics company engaged in antibody discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Genovac is listed as a partner logo, indicating a collaboration with an antibody discovery and development biotech company.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

NGM Bio is listed as a partner logo. NGM Therapeutics is a biopharmaceutical company focused on discovering and developing novel biologics, indicating a collaborative discovery relationship.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Aethon Therapeutics is listed as a partner logo, representing a collaboration with a biotherapeutics company engaged in antibody and drug discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AdAlta is listed as a partner logo. AdAlta is an Australian biotech company developing antibody therapeutics using its i-body platform.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cerba Research is listed as a partner logo, representing a collaboration with a CRO specializing in preclinical and clinical research services for biologics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

RxBiologics is listed as a partner logo, indicating a collaboration with a biopharmaceutical company engaged in biologics development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Neogene Therapeutics is listed as a partner logo. Neogene is focused on T-cell receptor (TCR) engineered T-cell therapies, suggesting collaboration in novel biologics discovery.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Schrödinger operates a much broader computational chemistry, biology, and materials science platform with enterprise pharma customers. It is comparable as a higher-level incumbent offering predictive modeling and discovery software that overlaps with ENPICOM's AI-enabled biologics discovery workflow.

TypeDirect peer
Description

TetraScience operates a life sciences R&D data cloud that harmonizes instrument and experimental data for pharma customers, similar in architecture and enterprise pharma focus to ENPICOM. Both compete to be the connective tissue between wet lab data sources and analytical/AI workflows.

TypeDirect peer
Description

Dotmatics delivers a scientific informatics platform (LIMS, ELN, data management, analytics) widely used by pharma and biotech R&D organizations. It overlaps with ENPICOM's offering in laboratory data integration and discovery analytics for biologics programs.

TypeBroad incumbent
Description

Veeva provides cloud software for life sciences, including R&D, quality, regulatory, and commercial domains used by most large pharma companies. It is a broad incumbent whose R&D cloud product competes for the same enterprise life sciences IT wallet that ENPICOM addresses.

TypeDirect peer
Description

Genedata provides enterprise bioinformatics and R&D informatics solutions for pharma, industrial biotech, and diagnostics, including specialized biologics screening and characterization workflows. It is directly comparable to ENPICOM's enterprise biologics bioinformatics positioning and long-running pharma customer footprint.

TypeDirect peer
Description

DNAnexus provides a cloud-based biomedical data analysis and management platform used by pharma, biotech, and clinical labs for genomics and multi-omics workflows. It is directly comparable to ENPICOM as a bioinformatics SaaS serving enterprise life sciences customers with similar data integration and pipeline orchestration capabilities.

TypeDirect peer
Description

IDBS provides ELN, LIMS, and bioprocess informatics used by global biopharma R&D and manufacturing organizations. It is comparable to ENPICOM as an enterprise life sciences data management and workflow platform with deep pharma penetration.

TypeEmerging player
Description

AbCellera is a clinical-stage biotech that combines a proprietary antibody discovery platform with AI/ML capabilities to identify lead candidates for partners. It is comparable to ENPICOM as a technology-forward antibody discovery player, though AbCellera integrates wet-lab capabilities ENPICOM does not own.

TypeEmerging player
Description

Specifica developed antibody discovery libraries and analytics tooling for therapeutic antibody generation, focusing on in vitro display-based discovery. It is comparable to ENPICOM as a niche antibody discovery technology platform with overlapping customer base among biotech and pharma R&D teams.

TypeDirect peer
Description

Benchling offers a cloud R&D platform spanning ELN, LIMS, registration, and molecular biology workflows used by leading pharma and biotech companies. It is directly comparable because it competes for the same enterprise R&D informatics budget and increasingly covers biologics and antibody engineering use cases that ENPICOM targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ENPICOM

Bioinformatics Software for Antibody & Biologics Discoveryenpicom.com

ENPICOM B.V. is a Netherlands-based bioinformatics software company (founded 2015) that provides a SaaS discovery operating system for antibody and immune-repertoire workflows, serving top-10 pharma, biotech, and academic customers with integrated pipeline automation, ML, and AI-agent capabilities.

What ENPICOM does

ENPICOM B.V. is a Netherlands-based bioinformatics software company founded in 2015 and headquartered in 's-Hertogenbosch. The company builds the ENPICOM Platform, a SaaS-based discovery operating system designed specifically for biologics — primarily antibody and immune-repertoire discovery workflows used by pharmaceutical and biotechnology companies. The platform processes NGS, Sanger, and single-cell sequencing data at scale, delivering end-to-end pipelines for in vitro and in vivo antibody lead selection, including clone annotation, quality control, clonotype clustering, enrichment analysis, developability analysis, and candidate prioritization.

The technology stack is biologics-specific rather than generic lab automation, with integrated modules covering pipeline automation, an AI Agent interface (exposed via the Model Context Protocol), ML model integration, and system integration with existing LIMS, ELNs, data lakes, and CRO deliverables. ENPICOM holds ISO 27001 certification and deploys engineering teams alongside client scientists to scope and build tailored pipelines, typically live within 4-8 weeks. The company also produces the 'Models & Molecules' podcast as a content and thought-leadership channel.

ENPICOM operates a direct enterprise sales motion with quote-based annual subscriptions and bundled professional services for pipeline deployment. The customer base spans top-10 pharmaceutical companies, biotech firms, academic institutions, and a network of 27+ partner organizations including Illumina, Carterra, LifeArc, NGM Bio, and Erasmus MC. Total disclosed equity funding is approximately $1.36 million across two rounds (2015 and 2019), with investors including Arches Capital, BOM Brabant Ventures, NextGen Ventures, and ACE Incubator. The leadership team is led by founder and CEO Nicola Bonzanni, with Jorrit Posthuma as CTO, Pim Fuchs as CAIO, Pablo Mendes de León as CFO & COO, and Ron van Eijsden as CBO.

ENPICOM firmographics

Firmographics
Name
ENPICOM
Legal name
ENPICOM B.V.
Website
https://enpicom.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
ENPICOM B.V. is a Netherlands-based bioinformatics software company (founded 2015) that provides a SaaS discovery operating system for antibody and immune-repertoire workflows, serving top-10 pharma, biotech, and academic customers with integrated pipeline automation, ML, and AI-agent capabilities.
Ownership category
akta.pro rank

ENPICOM industry classification

Industry
Product category
Bioinformatics Software for Antibody & Biologics Discovery
NAICS
Software Publishers (513210), Computer Systems Design and Related Services (54151)
SIC
Services-Prepackaged Software (7372), Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Bioinformatics software
  • Antibody discovery
  • Biologics analytics
  • Immune repertoire analysis
  • Sequencing data platform

Where ENPICOM is headquartered

Location

Headquarters

HQ city
Den Bosch
HQ country
Netherlands
HQ region
Europe

Offices1 record

Markets served

ENPICOM business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. SaaS Platform Subscription: ENPICOM provides its discovery platform as a SaaS product. Customers pay subscription fees for access to the platform, with pipeline deployment and engineering support included as part of the engagement. Terms indicate automatic annual renewal unless terminated two months before expiry.
  2. Professional Services (Pipeline Deployment): ENPICOM deploys a team of engineers alongside client scientists to scope, build, and deploy tailored discovery pipelines within 4-8 weeks. This engineering deployment is a core component of the commercial engagement model.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualNo public tier structure disclosed

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

ENPICOM product offering

Product offering

Core offering

ENPICOM provides a SaaS-based discovery operating system that ingests sequencing data and applies AI- and ML-driven analytics for antibody and biologics discovery. The platform supports in vitro and in vivo discovery workflows, automates end-to-end pipelines, and exposes an MCP-based Agent Interface so AI agents can interact with discovery data. The offering is targeted at pharma, biotech, and academic researchers developing therapeutic antibodies and other biologics.

Product overview

ENPICOM offers a unified platform-plus-modules architecture centered on the ENPICOM Platform — a discovery operating system for biologics. The core platform provides end-to-end analysis-workflow orchestration for immune-repertoire and antibody sequence analysis, processing billions of sequences in hours. The product portfolio comprises two primary solution modules — In vitro Antibody Discovery and In vivo Antibody Discovery — which cover clone annotation, quality control, clonotype clustering, enrichment analysis, developability analysis, and candidate prioritization. Supporting capability modules include Pipeline Automation, Agent Interface, AI Adoption (ML model integration), and System Integration. ENPICOM also produces the Models & Molecules Podcast as a content/marketing sub-brand. Note: An older IGX Platform is referenced in historical terms and conditions but appears superseded by the current ENPICOM Platform.

Differentiator

Problem solved

Functional benefit

Brands

  • ENPICOM Platform: The operating system for biologics discovery - a software platform providing end-to-end environment for analysis-workflow orchestration covering immune-repertoire and antibody sequence analysis, data integration, assay and screening management, and developability tracking.
  • Models & Molecules Podcast

Quantifiable outcome

  • 4× faster pipeline deployment — pipelines live in 4-8 weeks, not a 12-month implementation project
  • +7 more outcomes

Companies that use ENPICOM

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

ENPICOM technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature8 records

ENPICOM partnerships and signals

Strategic signal

Partnerships

27 partnerships are on record, tiered core.

  • IlluminacoreTechnology or IntegrationIllumina is listed as a partner logo on ENPICOM's website, indicating a technology integration or collaboration. Illumina provides next-generation sequencing (NGS) platforms that are a core data source for ENPICOM's discovery pipelines. ENPICOM connects to sequencing platforms including Illumina as part of its end-to-end pipeline automation.
  • CarterracoreTechnology or IntegrationCarterra is listed as a partner logo. Carterra provides high-throughput antibody screening and characterization platforms. The partnership integrates Carterra's experimental data with ENPICOM's analytical pipelines.
  • LifeArccoreStrategic or Co-development PartnerLifeArc is listed as a partner logo. LifeArc is a UK-based medical research charity engaged in translational biomedical research and drug discovery, indicating a co-development or strategic collaboration in antibody discovery.
  • Erasmus MCcoreStrategic or Co-development PartnerErasmus MC (Erasmus University Medical Center Rotterdam) is listed as a partner logo, representing a strategic collaboration with a leading academic medical center for biologics and immunology research.
  • University of OxfordcoreStrategic or Co-development PartnerUniversity of Oxford is listed as a partner logo. The collaboration connects ENPICOM's discovery platform with Oxford's academic research capabilities in antibody discovery and immunology.
  • Weizmann InstitutecoreStrategic or Co-development PartnerWeizmann Institute of Science is listed as a partner logo. The collaboration provides access to cutting-edge immunology research capabilities for biologics discovery.
  • UCL (University College London)coreStrategic or Co-development PartnerUCL is listed as a partner logo, representing a collaboration with one of the UK's leading research universities for biologics and computational biology research.
  • Radboud UniversitycoreStrategic or Co-development PartnerRadboud University (Nijmegen, Netherlands) is listed as a partner logo, indicating a collaboration in academic biologics and immunology research.
  • Ghent UniversitycoreStrategic or Co-development PartnerGhent University (Universiteit Gent) is listed as a partner logo, representing a research collaboration in biologics discovery.
  • VU AmsterdamcoreStrategic or Co-development PartnerVU Amsterdam is listed as a partner logo, indicating a research collaboration with one of Amsterdam's major universities in the field of immunology and biologics.
  • Utrecht UniversitycoreStrategic or Co-development PartnerUtrecht University is listed as a partner logo, representing a collaboration with a leading Dutch research university in antibody and biologics research.
  • Aalborg UniversitycoreStrategic or Co-development PartnerAalborg University (Denmark) is listed as a partner logo, indicating a research collaboration in computational biology and biologics discovery.
  • TUM (Technical University of Munich)coreStrategic or Co-development PartnerTUM is listed as a partner logo, representing a collaboration with a leading German technical university in computational life sciences and biologics research.
  • KGI (Keck Graduate Institute)coreStrategic or Co-development PartnerKGI is listed as a partner logo. Keck Graduate Institute in Claremont, CA specializes in applied life sciences and biotech, indicating a collaboration in biologics education and/or research.
  • University of MichigancoreStrategic or Co-development PartnerUniversity of Michigan is listed as a partner logo, representing a collaboration with a leading US research university in computational biology and antibody discovery.
  • Queen Mary University of LondoncoreStrategic or Co-development PartnerQueen Mary University of London is listed as a partner logo, indicating a research collaboration in biologics and immunology.
  • Inno4vaccoreStrategic or Co-development PartnerInno4vac is listed as a partner logo. Inno4vac is focused on innovation in vaccine and immunotherapy development, suggesting a collaborative effort in biologics discovery methodologies.
  • MabyloncoreStrategic or Co-development PartnerMabylon is listed as a partner logo, representing a collaboration with a biotech company engaged in antibody discovery and development.
  • Memo TherapeuticscoreStrategic or Co-development PartnerMemo Therapeutics is listed as a partner logo, indicating a collaborative relationship with a biotech company specializing in antibody discovery.
  • Kling BiotherapeuticscoreStrategic or Co-development PartnerKling Biotherapeutics is listed as a partner logo, representing a collaboration with a biotherapeutics company engaged in antibody discovery.
  • GenovaccoreStrategic or Co-development PartnerGenovac is listed as a partner logo, indicating a collaboration with an antibody discovery and development biotech company.
  • NGM BiocoreStrategic or Co-development PartnerNGM Bio is listed as a partner logo. NGM Therapeutics is a biopharmaceutical company focused on discovering and developing novel biologics, indicating a collaborative discovery relationship.
  • Aethon TherapeuticscoreStrategic or Co-development PartnerAethon Therapeutics is listed as a partner logo, representing a collaboration with a biotherapeutics company engaged in antibody and drug discovery.
  • AdAltacoreStrategic or Co-development PartnerAdAlta is listed as a partner logo. AdAlta is an Australian biotech company developing antibody therapeutics using its i-body platform.
  • Cerba ResearchcoreStrategic or Co-development PartnerCerba Research is listed as a partner logo, representing a collaboration with a CRO specializing in preclinical and clinical research services for biologics.
  • RxBiologicscoreStrategic or Co-development PartnerRxBiologics is listed as a partner logo, indicating a collaboration with a biopharmaceutical company engaged in biologics development.
  • Neogene TherapeuticscoreStrategic or Co-development PartnerNeogene Therapeutics is listed as a partner logo. Neogene is focused on T-cell receptor (TCR) engineered T-cell therapies, suggesting collaboration in novel biologics discovery.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

ENPICOM competitors and assessment

Company assessment

Broad incumbents

  • Schrödinger: Schrödinger operates a much broader computational chemistry, biology, and materials science platform with enterprise pharma customers. It is comparable as a higher-level incumbent offering predictive modeling and discovery software that overlaps with ENPICOM's AI-enabled biologics discovery workflow.
  • Veeva Systems: Veeva provides cloud software for life sciences, including R&D, quality, regulatory, and commercial domains used by most large pharma companies. It is a broad incumbent whose R&D cloud product competes for the same enterprise life sciences IT wallet that ENPICOM addresses.

Direct peers

  • TetraScience: TetraScience operates a life sciences R&D data cloud that harmonizes instrument and experimental data for pharma customers, similar in architecture and enterprise pharma focus to ENPICOM. Both compete to be the connective tissue between wet lab data sources and analytical/AI workflows.
  • Dotmatics: Dotmatics delivers a scientific informatics platform (LIMS, ELN, data management, analytics) widely used by pharma and biotech R&D organizations. It overlaps with ENPICOM's offering in laboratory data integration and discovery analytics for biologics programs.
  • Genedata: Genedata provides enterprise bioinformatics and R&D informatics solutions for pharma, industrial biotech, and diagnostics, including specialized biologics screening and characterization workflows. It is directly comparable to ENPICOM's enterprise biologics bioinformatics positioning and long-running pharma customer footprint.
  • DNAnexus: DNAnexus provides a cloud-based biomedical data analysis and management platform used by pharma, biotech, and clinical labs for genomics and multi-omics workflows. It is directly comparable to ENPICOM as a bioinformatics SaaS serving enterprise life sciences customers with similar data integration and pipeline orchestration capabilities.
  • IDBS: IDBS provides ELN, LIMS, and bioprocess informatics used by global biopharma R&D and manufacturing organizations. It is comparable to ENPICOM as an enterprise life sciences data management and workflow platform with deep pharma penetration.
  • Benchling: Benchling offers a cloud R&D platform spanning ELN, LIMS, registration, and molecular biology workflows used by leading pharma and biotech companies. It is directly comparable because it competes for the same enterprise R&D informatics budget and increasingly covers biologics and antibody engineering use cases that ENPICOM targets.

Emerging players

  • AbCellera Biologics: AbCellera is a clinical-stage biotech that combines a proprietary antibody discovery platform with AI/ML capabilities to identify lead candidates for partners. It is comparable to ENPICOM as a technology-forward antibody discovery player, though AbCellera integrates wet-lab capabilities ENPICOM does not own.
  • Specifica (an Astellas company): Specifica developed antibody discovery libraries and analytics tooling for therapeutic antibody generation, focusing on in vitro display-based discovery. It is comparable to ENPICOM as a niche antibody discovery technology platform with overlapping customer base among biotech and pharma R&D teams.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ENPICOM social profiles

Digital presence

ENPICOM compliance and trust

Trust signal

Compliance1 record

ENPICOM financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ENPICOM leadership team

Management profile

Number of profiles

Profiles5 records

ENPICOM funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ENPICOM M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENPICOM

What does ENPICOM do?

ENPICOM provides a SaaS-based discovery operating system that ingests sequencing data and applies AI- and ML-driven analytics for antibody and biologics discovery. The platform supports in vitro and in vivo discovery workflows, automates end-to-end pipelines, and exposes an MCP-based Agent Interface so AI agents can interact with discovery data. The offering is targeted at pharma, biotech, and academic researchers developing therapeutic antibodies and other biologics.

Is ENPICOM a public or private company?

ENPICOM is a private company. It is classified as venture growth investor backed and is currently operating.

When was ENPICOM founded?

ENPICOM was founded in 2015. It employs 11 to 50 people.

Where is ENPICOM based?

ENPICOM is headquartered in Den Bosch, Netherlands, in the Europe region.

How does ENPICOM make money?

Two revenue lines are on record. SaaS Platform Subscription is the primary driver. The others are professional Services (Pipeline Deployment).

Who are ENPICOM's main competitors?

Broad incumbents on record are Schrödinger and Veeva Systems. Direct peers are TetraScience, Dotmatics, Genedata, DNAnexus, IDBS and Benchling. Emerging players are AbCellera Biologics and Specifica (an Astellas company).

Does ENPICOM have an API?

No public API is recorded for ENPICOM.

What industry is ENPICOM in?

ENPICOM's product category is Bioinformatics Software for Antibody & Biologics Discovery. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals